Blockade of IL-17RB by SM17 is expected to interfere with IL-25 signaling, subsequently reducing the Th2-mediated inflammatory response, such as a reduction in cytokine release and eosinophilia in patients. This evidence concerns the gene IL25 and Increased total eosinophil count.